Intermittent Claudication - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 70 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Intermittent Claudication - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Intermittent Claudication - Pipeline Review, H2 2014', provides an overview of the Intermittent Claudication's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Intermittent Claudication, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Intermittent Claudication and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Intermittent Claudication
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Intermittent Claudication and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Intermittent Claudication products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Intermittent Claudication pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Intermittent Claudication
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Intermittent Claudication pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Intermittent Claudication Overview 7
Therapeutics Development 8
Pipeline Products for Intermittent Claudication - Overview 8
Pipeline Products for Intermittent Claudication - Comparative Analysis 9
Intermittent Claudication - Therapeutics under Development by Companies 10
Intermittent Claudication - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Intermittent Claudication - Products under Development by Companies 13
Intermittent Claudication - Companies Involved in Therapeutics Development 14
Cytokinetics, Inc. 14
DNAVEC Corporation 15
Genovate Biotechnology Co., LTD. 16
Kowa Company, Ltd. 17
LTT Bio-Pharma Co., Ltd. 18
Nuo Therapeutics, Inc. 19
Pluristem Therapeutics Inc. 20
Rigel Pharmaceuticals, Inc. 21
Taisho Toyama Pharmaceutical Co., Ltd. 22
Intermittent Claudication - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
ALD-301 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
alprostadil - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
cilostazol CR - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
CK-2066260 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
DVC1-0101 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
ecraprost - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
K-134 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
LT-0101 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
R-118 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
tirasemtiv - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Intermittent Claudication - Recent Pipeline Updates 49
Intermittent Claudication - Dormant Projects 61
Intermittent Claudication - Discontinued Products 62
Intermittent Claudication - Product Development Milestones 63
Featured News & Press Releases 63
Mar 06, 2014: Rigel Announces Publication of R118 AMPK Activator Research 63
Nov 13, 2013: Pluristem Receives Regulatory Approval to Extend Its Phase II Study of PLX-PAD Cells in the Treatment of Intermittent Claudication to South Korea 64
Oct 02, 2013: Pluristem Receives Israeli Ministry of Health Approval to Expand Its Phase II Clinical Trial in Intermittent Claudication to Israel 64
Sep 16, 2013: FDA Lifts Clinical Hold of Pluristem's Phase II Intermittent Claudication Study 65
Jul 08, 2013: Pluristem's South Korean Partner Files IND With Korean FDA for PLX Cells 65
Jun 04, 2013: Pluristem To Receive Clinical-hold Notice From FDA For US Phase II Intermittent Claudication Study 65
Jan 15, 2013: Pluristem Receives Approval To Expand Phase II Clinical Trial In Intermittent Claudication To Germany 66
Aug 23, 2012: Pluristem Commences Phase II Clinical Trial For Intermittent Claudication Using PLX Cells 66
Aug 13, 2012: Pluristem Moves Intermittent Claudication Indication Forward in Germany Through Collaboration With Cato Research 67
Jul 18, 2012: Pluristem Partners With CPC Clinical Research For Peripheral Artery Disease Study 67
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 70
Disclaimer 70

List of Tables
Number of Products under Development for Intermittent Claudication, H2 2014 8
Number of Products under Development for Intermittent Claudication - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Intermittent Claudication - Pipeline by Cytokinetics, Inc., H2 2014 14
Intermittent Claudication - Pipeline by DNAVEC Corporation, H2 2014 15
Intermittent Claudication - Pipeline by Genovate Biotechnology Co., LTD., H2 2014 16
Intermittent Claudication - Pipeline by Kowa Company, Ltd., H2 2014 17
Intermittent Claudication - Pipeline by LTT Bio-Pharma Co., Ltd., H2 2014 18
Intermittent Claudication - Pipeline by Nuo Therapeutics, Inc., H2 2014 19
Intermittent Claudication - Pipeline by Pluristem Therapeutics Inc., H2 2014 20
Intermittent Claudication - Pipeline by Rigel Pharmaceuticals, Inc., H2 2014 21
Intermittent Claudication - Pipeline by Taisho Toyama Pharmaceutical Co., Ltd., H2 2014 22
Assessment by Monotherapy Products, H2 2014 23
Number of Products by Stage and Target, H2 2014 25
Number of Products by Stage and Mechanism of Action, H2 2014 27
Number of Products by Stage and Route of Administration, H2 2014 29
Number of Products by Stage and Molecule Type, H2 2014 31
Intermittent Claudication Therapeutics - Recent Pipeline Updates, H2 2014 49
Intermittent Claudication - Dormant Projects, H2 2014 61
Intermittent Claudication - Discontinued Products, H2 2014 62